Rebecca Edelmayer, PhD, Alzheimer’s Association, introduces the recently established Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET) initiative. ALZ-NET was launched by the Alzheimer’s Association as a way to gather data on the real-world use of novel FDA-approved Alzheimer’s disease treatments, to inform future research and improve patient care. The network will collect longitudinal diagnostic and therapeutic data, to offer better insights into the long-term health outcomes for patients receiving these therapies. Real-world data also encompasses a much more diverse population than that of clinical trials. ALZ-NET seeks to foster continuous learning, providing information to health care providers on how to improve diagnosis and care, as well as advancing the science behind future Alzheimer’s disease treatments.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
